In a report released today, Matthew Biegler from Oppenheimer maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $10.26.
Biegler covers the Healthcare sector, focusing on stocks such as Tyra Bioscience, Regeneron, and IDEAYA Biosciences. According to TipRanks, Biegler has an average return of -1.2% and a 35.51% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oric Pharmaceuticals with a $18.83 average price target, an 83.53% upside from current levels. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $17.00 price target.
ORIC market cap is currently $723.8M and has a P/E ratio of -5.82.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Oric Pharmaceuticals (ORIC) Company Description:
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.
Read More on ORIC:
- Oric Pharmaceuticals reports Q3 EPS (49c), consensus (48c)
- ORIC Earnings this Week: How Will it Perform?
- Wingstop upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls
- Wells starts Oric Pharmaceuticals with Overweight into ‘de-risking catalysts’
- Oric Pharmaceuticals initiated with an Overweight at Wells Fargo
